Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models

Figure 3

Therapeutic effects of MT-1303 and FK506 on established proteinuria in aged MRL/lpr mice. MT-1303 and FK506 were orally administered to MRL/lpr mice with a proteinuria score of 2 from 20 to 26 weeks of age. Proteinuria was assessed once a week using Ames urinalysis strips. (a, b) Proteinuria scores following administration of MT-1303 (a) and FK506 (b) are expressed as the of 16 mice. Statistical differences were calculated using the Shirley-Williams test by comparison with the control (, ). (c, d) The incidence of proteinuria in MT-1303 groups (c) and FK506 groups (d) is expressed as the proportion of proteinuria-positive mice () from a total of 16 mice. Statistical differences were calculated using Fisher’s exact test with Hommel’s multiple comparison test by comparison with the control (, ). (e–h) Kidney sections from vehicle- (e, g) or MT-1303 0.3 mg/kg- (f, h) treated mice were stained with anti-mouse CD3 mAb (e, f) or HE (g, h).